Moleculin Biotech Inc (MBRX) — Financial Flexibility Index
Moleculin Biotech Inc (MBRX) has a Financial Flexibility Index of -0.75x as of December 2025. Free cash flow of $-5.37 Million (operating CF $-5.37 Million minus capex $0.00) represents -1% of total liabilities ($7.12 Million). Check MBRX goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Moleculin Biotech Inc Financial Flexibility Index (2015–2025)
Historical Financial Flexibility Index trend for Moleculin Biotech Inc across 11 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Moleculin Biotech Inc.
Annual Financial Flexibility Index for Moleculin Biotech Inc (2015–2025)
Year-by-year free cash flow to debt coverage for Moleculin Biotech Inc. Explore MBRX cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -3.19x | $-22.73 Million | $-22.73 Million | $7.12 Million | ▼ -46.6% |
| 2024 | -2.18x | $-23.85 Million | $-23.86 Million | $10.95 Million | ▼ -10.4% |
| 2023 | -1.97x | $-23.98 Million | $-24.10 Million | $12.14 Million | ▲ +62.5% |
| 2022 | -5.27x | $-27.57 Million | $-27.64 Million | $5.23 Million | ▼ -41.9% |
| 2021 | -3.71x | $-18.93 Million | $-18.95 Million | $5.10 Million | ▼ -140.7% |
| 2020 | -1.54x | $-17.39 Million | $-17.77 Million | $11.27 Million | ▲ +13.0% |
| 2019 | -1.77x | $-17.15 Million | $-17.20 Million | $9.66 Million | ▲ +20.0% |
| 2018 | -2.22x | $-11.79 Million | $-12.20 Million | $5.31 Million | ▲ +28.1% |
| 2017 | -3.08x | $-7.30 Million | $-7.32 Million | $2.37 Million | ▼ -18.1% |
| 2016 | -2.61x | $-3.74 Million | $-3.76 Million | $1.43 Million | ▼ -401.7% |
| 2015 | -0.52x | $-402.51K | $-423.51K | $772.79K | — |